BACKGROUND: Accumulating evidence suggests that the tumor suppressor gene Kruppel-like factor 6 (KLF6) and its dominant-negative splice form KLF6-SV1 play important roles in both the development and progression of cancer. However, the role of KLF6-SV1 in gastric cancer remains largely unknown. METHODS: KLF6-SV1 expression was detected in various human gastric cancer cell lines and gastric cancer patient samples by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting. Small interfering RNA (siRNA) was used to inhibit KLF6-SV1 expression in BGC-823 and SGC-7901 cell lines. The effects of downregulation of KLF6-SV1 by siRNA on cell proliferation, migration, invasion, and tumor growth were examined in vitro and in vivo. RESULTS: Overexpression of KLF6-SV1 was detected in tumor samples from gastric cancer patients, and in various differentiated gastric cancer cell lines. In vitro downregulation of KLF6-SV1 by siRNA inhibited BGC-823 and SGC-7901 cell proliferation, anchorage-independent growth, migration, and invasion through the altered expression of Ki-67, vascular endothelial growth factor (VEGF), E-cadherin, and matrix metalloproteinase (MMP)-9. Also, KLF6-SV1 silencing promoted caspase-dependent apoptosis of BGC-823 and SGC-7901 cells via the regulation of phosphatidylinositol 3-OH kinase (PI3K)/Akt activity and Bcl-2-related protein expression. In vivo animal studies showed that KLF6-SV1 siRNA significantly inhibited the tumorigenicity of BGC-823 and SGC-7901 cells. Gene therapy with polyethylenimine/si-SV1 intratumoral injection also resulted in the suppression of tumor growth and prolonged animal survival in an established xenograft tumor model. CONCLUSION: These data demonstrate that KLF6-SV1 is an important regulator of the growth, migration, invasion, and survival of gastric cancer cells, and downregulation of KLF6-SV1 by siRNA may offer a new potential gene therapy approach for gastric cancer.
BACKGROUND: Accumulating evidence suggests that the tumor suppressor gene Kruppel-like factor 6 (KLF6) and its dominant-negative splice form KLF6-SV1 play important roles in both the development and progression of cancer. However, the role of KLF6-SV1 in gastric cancer remains largely unknown. METHODS:KLF6-SV1 expression was detected in various humangastric cancer cell lines and gastric cancerpatient samples by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting. Small interfering RNA (siRNA) was used to inhibit KLF6-SV1 expression in BGC-823 and SGC-7901 cell lines. The effects of downregulation of KLF6-SV1 by siRNA on cell proliferation, migration, invasion, and tumor growth were examined in vitro and in vivo. RESULTS: Overexpression of KLF6-SV1 was detected in tumor samples from gastric cancerpatients, and in various differentiated gastric cancer cell lines. In vitro downregulation of KLF6-SV1 by siRNA inhibited BGC-823 and SGC-7901 cell proliferation, anchorage-independent growth, migration, and invasion through the altered expression of Ki-67, vascular endothelial growth factor (VEGF), E-cadherin, and matrix metalloproteinase (MMP)-9. Also, KLF6-SV1 silencing promoted caspase-dependent apoptosis of BGC-823 and SGC-7901 cells via the regulation of phosphatidylinositol 3-OH kinase (PI3K)/Akt activity and Bcl-2-related protein expression. In vivo animal studies showed that KLF6-SV1 siRNA significantly inhibited the tumorigenicity of BGC-823 and SGC-7901 cells. Gene therapy with polyethylenimine/si-SV1 intratumoral injection also resulted in the suppression of tumor growth and prolonged animal survival in an established xenograft tumor model. CONCLUSION: These data demonstrate that KLF6-SV1 is an important regulator of the growth, migration, invasion, and survival of gastric cancer cells, and downregulation of KLF6-SV1 by siRNA may offer a new potential gene therapy approach for gastric cancer.
Authors: Goutham Narla; Analisa DiFeo; Shen Yao; Asoka Banno; Eldad Hod; Helen L Reeves; Rui F Qiao; Olga Camacho-Vanegas; Alice Levine; Alexander Kirschenbaum; Andrew M Chan; Scott L Friedman; John A Martignetti Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Goutham Narla; Analisa Difeo; Helen L Reeves; Daniel J Schaid; Jennifer Hirshfeld; Eldad Hod; Amanda Katz; William B Isaacs; Scott Hebbring; Akira Komiya; Shannon K McDonnell; Kathleen E Wiley; Steven J Jacobsen; Sarah D Isaacs; Patrick C Walsh; S Lilly Zheng; Bao-Li Chang; Danielle M Friedrichsen; Janet L Stanford; Elaine A Ostrander; Arul M Chinnaiyan; Mark A Rubin; Jianfeng Xu; Stephen N Thibodeau; Scott L Friedman; John A Martignetti Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701
Authors: Yong Gu Cho; Chang Jae Kim; Cho Hyun Park; Young Mok Yang; Su Young Kim; Suk Woo Nam; Sug Hyung Lee; Nam Jin Yoo; Jung Young Lee; Won Sang Park Journal: Oncogene Date: 2005-06-30 Impact factor: 9.867
Authors: Sharon Benzeno; Goutham Narla; Jorge Allina; George Z Cheng; Helen L Reeves; Michaela S Banck; Joseph A Odin; J Alan Diehl; Doris Germain; Scott L Friedman Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Analisa Difeo; Fei Huang; Jaya Sangodkar; Esteban A Terzo; Devin Leake; Goutham Narla; John A Martignetti Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701
Authors: Diana Vetter; Michal Cohen-Naftaly; Augusto Villanueva; Youngmin A Lee; Peri Kocabayoglu; Rebekka Hannivoort; Goutham Narla; Josep M Llovet; Swan N Thung; Scott L Friedman Journal: Hepatology Date: 2012-08-27 Impact factor: 17.425
Authors: Raheleh Hatami; Anieta M Sieuwerts; Sudeh Izadmehr; Zhong Yao; Rui Fang Qiao; Luena Papa; Maxime P Look; Marcel Smid; Jessica Ohlssen; Alice C Levine; Doris Germain; David Burstein; Alexander Kirschenbaum; Analisa DiFeo; John A Foekens; Goutham Narla Journal: Sci Transl Med Date: 2013-01-23 Impact factor: 17.956